Niraparib

Category: Cancer



Niraparib Overview

Niraparib (trade name Zejula) is an orally active[1] small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016.[2] It was approved on 27 March 2017 in the US,[3] and has been approved in Europe on 16 November 2017[4]. Contents 1 Medical uses 2 Contraindications 3 Side ...

Read more Niraparib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib

Recent Niraparib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Niraparib
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Niraparib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA